Scientific collaborators at Indiana University School of Medicine presented preclinical data showing Ashvattha’s hydroxyl dendrimers (HDs) were selectively taken up only within tumor-associated microglia/macrophages in
– Scientific collaborators at Indiana University School of Medicine will present preclinical data demonstrating Ashvattha’s hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform
REDWOOD CITY, Calif., May 5, 2022 – Ashvattha Therapeutics, (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey Cleland, Ph.D.,
Data showed single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects D-4517.2 exposure in healthy subjects translates to efficacious doses in
Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced it has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine.
Ashvattha will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.
Ashvattha Chairman, CEO and President Jeffrey Cleland, Ph.D., will be presenting at various virtual and in-person investor conferences in September and October.
Ashvattha announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.
Ashvattha will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually on May 18-20
Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.